Ultrasound-guided continuous erector spinae block in postoperative analgesia after thoracoscopic surgery

Effect of continuous erector spinae plane block with dexamethasone compounded with ropivacaine on postoperative analgesia in patients undergoing thoracoscopic pulmonary nodule surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066531

Enrollment

Unknown

Registered

2022-12-08

Start date

2022-12-08

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary nodule

Interventions

Control group:Ropivacaine continuous erector spinae plane block

Experimental group:Continuous erector spinae plane block with dexamethasone compounded with ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. ASA grading 1-3; 3. Unilateral VATS under elective general anesthesia; 4. Patients requiring postoperative analgesia; 5. Participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with regional block contraindications; 2. Infected persons at the puncture site or throughout the body; 3. Previous or existing neurological impairment; 4. Surgical history, trauma history or chronic pain history at the puncture site; 5. Long-term use of glucocorticoid or allergy, and allergy to local anesthetics; 6. Patients expected to receive mechanical ventilation for poor pulmonary function after surgery; 7. Patients with VATS accidentally converted to thoracotomy during the operation or suffered massive bleeding during the operation; 8. Patients with heart disease and abnormal liver and kidney function; 9. Patients with a history of opioid abuse, alcoholism or long-term use of NSAIDS before surgery; 10. Patients unable to communicate and cooperate; 11. Taking other experimental drugs or participating in other clinical trials 3 months before study inclusion; 12. Unable to cooperate with the study for any reason or considered by the investigator not to be included in the trial.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale for postoperative pain;	—

Secondary

Measure	Time frame
Quality of post-operative recovery;Visual analogue scale for postoperative pain;Intraoperative and postoperative opioid consumption;The time required for initial analgesia and the number of remedial analgesia;Nausea, vomiting, dizziness, urinary retention, itchy skin, etc.;Time of first post-operative bed movement, first water intake and first bowel movement;Pre- and post-operative plasma levels of TNF-a, IL-6 and IL-8;	—

Measure

Time frame

Quality of post-operative recovery;Visual analogue scale for postoperative pain;Intraoperative and postoperative opioid consumption;The time required for initial analgesia and the number of remedial analgesia;Nausea, vomiting, dizziness, urinary retention, itchy skin, etc.;Time of first post-operative bed movement, first water intake and first bowel movement;Pre- and post-operative plasma levels of TNF-a, IL-6 and IL-8;

—

Countries

China

Contacts

Public ContactLi Hong

The Second Affiliated Hospital of the Army Medical University

lh78553@163.com+86 23 68774997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026